Renal transplantation for amyloid end-stage renal failure-insights from serial serum amyloid P component scintigraphy.
Although end-stage renal failure (ESRF) is common in systemic amyloidosis, few such patients receive renal transplants. Serum amyloid P component (SAP) scintigraphy is a specific method for the imaging and quantification of amyloid deposits in vivo, which has not previously been used to evaluate the outcome of renal transplantation in patients with amyloidosis. Evidence of renal graft amyloid was sought by SAP scintigraphy in 15 patients with systemic amyloidosis who had undergone renal transplantation 42-216 months (median, 73 months) previously. Prospective serial scans were obtained annually in eight cases. Renal grafts studied shortly after transplantation gave blood-pool images. The grafts remained normal in all patients whose underlying amyloidogenic disorder had remitted, whereas there was abnormal uptake of labelled SAP, indicating graft amyloidosis, in four out of 10 patients whose amyloid fibril precursor protein supply had not diminished. Graft amyloidosis was corroborated by renal dysfunction in each case, and by histology in one patient. SAP scintigraphy enables renal transplant grafts to be monitored noninvasively for involvement by amyloid. The lack of graft amyloidosis in all patients in whom the amyloidogenic underlying disorder had remitted, and in more than half of those in whom it had not, supports the use of renal transplantation for ESRF in systemic amyloidosis.